<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367670">
  <stage>Registered</stage>
  <submitdate>31/12/2014</submitdate>
  <approvaldate>22/04/2015</approvaldate>
  <actrnumber>ACTRN12615000367549</actrnumber>
  <trial_identification>
    <studytitle>Safety and efficacy of ketamine-dexmedetomidine combination versus dexmedetomidine alone in cirrhotic patients undergoing upper gastrointestinal-intestinal endoscopy: A prospective controlled clinical trial.</studytitle>
    <scientifictitle>Safety and Efficacy of Ketamine-dexmedetomidine  versus dexmedetomidine alone in cirrhotic patients undergoing upper gastrointestinal endoscopy. </scientifictitle>
    <utrn>U 1111-1165-6212</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Procedural sedation during UGIE in cirrhotic patients</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>GroupI(n=30):received I. V. Ketamine in a dose of 1 mg/ kg at induction of anesthesia followed by infusion of dexmedetomidine(dex) in a rate of 0.2-0.6ug/kg/hr till termination of endoscopy,  while GroupII(n=30) received only a continuous infusion of dex. at induction of anesthesia in a rate of 0.2-0.6ug/kg/hr guided by BIS range of 50-70  till termination of endoscopy. In both groups,fentanyl 25 ug/ kg was used  I.V as rescue sedoanalgesic when required</interventions>
    <comparator>The comparator/control treatment group is ketamine/dexmedetomidine group</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Efficacy: the proportion of complete procedures using the initial proposed sedation scheme . The sedation scheme was considered ineffective when the procedure was interrupted by agitation or intolerance by the patient despite the maximum sedative dose.</outcome>
      <timepoint>At termination of procedure.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Visual Analogue scale(VAS) was used to assess post-operative pain in the recovery period after attaining a modified Aldrete score of less than or equal to 10.</outcome>
      <timepoint>Every 15 min in the first hour and thereafter every 30 min until hospital discharge of patient.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>-Safety: frequencies of the following complications during procedure or recovery time;hypoxemia,hypotension, bradycardia - liver function tests in the third postoperative day  compared with the basal preprocedural level.</outcome>
      <timepoint>Every 2 min During the first 10 min of the procedure and thereafter every 5 min until termination of the procedure.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adult patients aged 18-60years with liver cirrhosis ,child-Pugh score A or B , referred for diagnostic and/ or therapeutic UGIE .</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Age less than 18 or more than 60 years, child- Pugh score C, need for emergency endoscopy ,hemodynamic ally unstable patients, significant cardio-pulmonary disease, hepatic encephalopathy,renal disease,use of sedatives or narcotics  one week prior to the endoscopy time,anticipated airway difficulties, allergy to the used drugs.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>2/06/2014</anticipatedstartdate>
    <actualstartdate>7/06/2014</actualstartdate>
    <anticipatedenddate>2/12/2014</anticipatedenddate>
    <actualenddate>20/12/2014</actualenddate>
    <samplesize>66</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>Qena</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>South valley university.</primarysponsorname>
    <primarysponsoraddress>SVU-Qena-postal code 85823</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>South valley university( SVU).</fundingname>
      <fundingaddress>SVU-Qena- postal code 85823</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress>Nil</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Ketamine/ dexmedetomidine combination versus dexmedetomidine alone for procedural sedation in cirrhotic patients undergoing UGIE regarding efficacy and safety.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Hatem Saber mohamed</name>
      <address>Qena university hospital-Qena- El-maabar street next to the faculty of nursing ,postal code 85823.</address>
      <phone>+201005257062</phone>
      <fax />
      <email>dr.hatem_saber@hotmail.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Gad sayed gad</name>
      <address>Qena university hospital-Qena-Elmaabar street next to the faculty of nursing ,postal code 85823.</address>
      <phone>+201099075675</phone>
      <fax />
      <email>alwafy35@yahoo.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Hatem saber mohamed</name>
      <address>Qena university hospital-Qena-Elmaabar street next to the faculty of nursing, postal code 85823.</address>
      <phone>+201005257062</phone>
      <fax />
      <email>dr.hatem_saber@hotmail.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>